|Home | About | Journals | Submit | Contact Us | Français|
Galectin-3 is expressed in a cell-type specific manner in human pituitary tumors and may have a role in pituitary tumor development. In this study, we hypothesized that Galectin-3 is regulated by RUNX proteins in pituitary tumors. Transcription factor prediction programs revealed several putative binding sites in the LGALS3 (Galectin-3 gene) promoter region. A human pituitary cell line HP75 was used as a model to study LGALS3 and RUNX interactions using Chromatin immunoprecipitation assay and electrophoresis mobility shift assay. Two binding sites for RUNX1 and one binding site for RUNX2 were identified in the LGALS3 promoter region. LGALS3 promoter was further cloned into a luciferase reporter, and the experiments showed that both RUNX1 and RUNX2 upregulated LGALS3. Knock-down of either RUNX1 or RUNX2 by siRNA resulted in a significant downregulation of Galectin-3 expression and decreased cell proliferation in the HP 75 cell line. Immunohistochemistry showed a close correlation between Galectin-3 expression and RUNX1/RUNX2 level in pituitary tumors. These results demonstrate a novel binding target for RUNX1 and RUNX2 proteins and suggest that Galectin-3 is regulated by RUNX1 and RUNX2 in human pituitary tumor cells by direct binding to the promoter region of LGALS3 and thus may contribute to pituitary tumor progression.
Galectin-3 (Gal-3) is a β-Galactoside-binding protein, which has important roles in diverse biological events, such as embryogenesis, cell adhesion, proliferation, apoptosis, mRNA splicing, and regulation of the immune system [1–3]. Gal-3 is expressed in various cells and tissues, such as activated macrophages, eosinophils, neutrophils, mast cells, epithelium of the gastrointestinal and respiratory tracts, kidneys and some sensory neurons, and is also involved in tumorigenesis, angiogenesis, and tumor metastasis [4, 5]. Gal-3 expression is increased in many tumors, including those of the pancreas, colon, and thyroid [6, 7]. Our previous studies showed that Gal-3 had an important role in promoting pituitary cell proliferation and tumor progression [8, 9]. However, the mechanism of Gal-3 regulation in pituitary tumors is not well understood.
Recent studies in mouse skeletal system showed that LGALS3 was regulated by RUNX2 through the binding to LGALS3 promoter . Another study using HOBIT, a human osteoblast-like cell line, showed that, after treatment with nucleotides (ATP and UTP), RUNX2 was highly expressed, and the Gal-3 protein level was also increased . We hypothesized that LGALS3 was regulated by RUNX proteins in human pituitary tumors.
RUNX protein family includes RUNX1, RUNX2, and RUNX3 which are all transcription factors containing a highly conserved region of 128 amino acids designated as the “runt homology domain (RHD),” and bind to a consensus sequence 5′-ACCPuCPu-3′ through the RHD, so RUNX1 and RUNX3 could also regulate LGALS3 in pituitary tumors. After screening with transcription factor prediction programs, we found two putative binding sites for RUNX1 and one site for RUNX2, but none for RUNX3 in the human LGALS3 promoter. We designed a series of overlapping PCR primers which covered the entire region of the LGALS3 promoter. Serial Chromatin Immunoprecipitation Assay (ChIP) performed with HP75 cells showed that one specific region in LGALS3 promoter was pulled down by anti-RUNX1 antibody while another specific region was pulled down by anti-RUNX2 antibody. Using Electrophoresis Mobility Shift Assay (EMSA), we found that HP75 nuclear extract specifically bound wild type oligonucleotides but not mutant oligonucleotides derived from the binding region of promoter. Luciferase reporter with the LGALS3 promoter demonstrated that LGALS3 was upregulated by RUNX1 and RUNX2, while siRNA knock-down of RUNX1 or RUNX2 significantly decreased Gal-3 expression and cell proliferation in HP75. These findings indicate that RUNX1 and RUNX2 may play important roles in human pituitary tumor through regulation of LGALS3.
The human pituitary adenoma cell line HP75  was maintained in DMEM (Invitrogeen, Carlsbad, CA) supplemented with 15% horse serum, 2.5% fetal bovine serum and 1 μg/ml insulin. As previously reported the HP75 cell line was derived from a non-functioning human pituitary adenoma and produces low levels of FSH in culture . HeLa (human cervical carcinoma) and SK-BR-3 (human breast adenocarcinoma) (ATCC, Manassas, VA) were grown in DMEM and McCoy’s 5A (Mediatech, Inc, Herndon, VA), respectively, with 10% fetal bovine serum. All media contain 1% Antibiotic-Antimycotic (100 units/ml penicillin G, 100 μg/ml streptomycin sulfate, and 250 ng/ml amphotericin B; Life Technologies, Inc., Grand Island, NY.). Cells were cultured in a humidified incubator at 37°C with 5% CO2.
Five pairs of PCR primers for ChIP were designed based on the human LGALS3 promoter sequence (Genbank AF031421. Table 1). Originally it was reported that the human LGALS3 promoter length is 977 bp , after comparison with the genomic sequence of LGALS 3 on Chromosome 14:54648570–54698569 and our sequencing results, we added 12 bp, so that the intact promoter length was 989 bp. We designed five pairs PCR primers to cover the human LGALS3 promoter from upstream to downstream (called region 1–5), see Table 1 and Fig. 1a.
Beta-actin (Genbank: M10277) was used as input control. Primers are 5′-ACA GAC TCC CCA TCC CAA GAC for sense and 5′-GAG GCG TAC AGG GAT AGC AC for antisense. Searching of DNA sequences for putative transcription factor-binding sites was performed using the web-based prediction programs MatInspector: Transfac, (http://transfac.gbf.de/) , TFSEARCH (www.cbrc.jp/research/db/TFSEARCH.html), TESS (Transcription Element Search System, http://www.cbil.upenn.edu/tess/), and TFBIND (http://tfbind.hgc.jp) . The MatInspector thresholds for core similarity and matrix similarity were set to 0.85 and 0.90, respectively. The TFSEARCH minimum score was set to 85.0 points. TFBIND minimum score was set to 90.0 points (default cutoff value) . TESS Maximum Allowable String Mismatch % (tmm) was set to 10, Minimum log-likelihood ratio score (ts-a) to 12, Minimum string length (tw) to 10. Putative RUNX-binding sites were identified by searching for sequences matching the published consensus sequence [10, 15–18]. Thus, the sequence was searched for the motif 5′-ACCPuCPu-3′ or its complementary sequence (YGYGGTY); positions 2 and 3 (CC) were considered to be most important. Two putative binding sites for RUNX1 and one putative binding site for RUNX2 were found in the LGALS3 promoter region (Fig. 1a). No binding site was found for RUNX3. The two binding sites for RUNX1 have same sequence (TCTGGT) and they are located in the upstream region of the LGALS3 promoter (−827 and −809, transcription start was defined as +1. This is called region 1) and very close (12 bp apart) to each other. RUNX2 binding sequence (CACCGCC) is located in the downstream region of the LGALS3 promoter (This is called region 5). For EMSA, we designed one oligonucleotide probe to cover the two putative binding sites of RUNX1, and another oligonucleotide to cover the putative binding site of RUNX2. In mutant types of oligonucleotides, the two GG were changed to CC in TCTGGT for RUNX1 or CC to GG in CACCGCC for RUNX2 (Table 2). Single-stranded oligonucleotides were purchased from IDT Inc. (Coralville, IA). Wild type and mutant type of oligonucleotides were labeled with biotin at 5′-end (hot probe); non-labeled wild-type (cold probe) was used as competitors.
The complementary oligonucleotides were dissolved in TE buffer (pH 8.0) and combined together, and then annealed in a PCR cycler. All annealed oligonucleotides were stored at −20°C.
ChIP assay Kit (Upstate Biotechnology, Lake Placid, NY) was used according to the method recommended by the manufacturer, with minor modifications. In brief, 1 × 106 HP75 cells were plated on a 10 cm dish, and fixed in the presence of 1% formaldehyde for 10 min at 37°C. A soluble chromatin fraction containing fragmented DNA of approximately 200–500 bp was obtained after cell lysis and sonication. The sonication was set as follows with an Ultrasonic Processor GEX130 sonicator (Cole-Parmer Instruments, Vernon Hills, IL): 50% output power, 20 cycles of 10 s sonication, resting 10 s between cycles. Pre-cleared lysates were aliquoted in two parts with equal volume. One aliquot was subject to ChIP by incubating with 5 μg of anti-RUNX1 or anti-RUNX2 or anti-RUNX3 polyclonal antibody overnight (Calbiochem, La Jolla, CA), the other aliquot was immnunoprecipitated using rabbit-IgG as a control with the same procedure. Immnunoprecipitated DNA was extracted by phenol/chloroform/isoamyl alcohol. The DNA was resuspended in TE buffer and stored at −20°C for PCR analysis. PCR reactions were performed using 1 μl of sample or 1 μl from 1:100 dilution of input. Pilot experiments were done to ensure that the number of cycles was within the range of exponential amplification. ChIP assays were repeated at least 3 times for each of anti-RUNX1, anti-RUNX2, and anti-RUNX3 antibodies. Positive controls (input chromatin DNA before immunoprecipitation) and negative controls (mock immunoprecipitation with rabbit-IgG) were run in each experiment. Beta-actin was used as another internal control.
Nuclear extracts were prepared using the NucBuster protein extraction kit (Novagen, Inc., Madison, WI.) as recommended by the manufacturer. The protein concentration in nuclear extracts was measured using a WPA Biowave Spectrophotometer (Brinkmann Instruments Inc., Westbury, NY) and the samples were stored in aliquots at −80°C.
Binding reactions were performed using the LightShift EMSA kit (Pierce, Rockford, IL) according to the manufacturer’s instructions. About 20 μg of nuclear extract and 20 fmol of biotin-labeled double-stranded oligonucleotide probes were used in the binding reaction. For competition assays, unlabeled double stranded probes were added to the reaction mixture prior to addition of the labeled probes with an excess of 200-fold molar concentrations. For supershift reactions, 1 μg of anti-RUNX1 or anti-RUNX2 antibodies (Biochem, La Jolla, CA.) was added to the EMSA reaction mixture 20 min before the biotin-labeled probes were added. EBNA system was run as a control per instruction in the kit manual. Signal was detected by Biotin-Streptavidin-HRP conjugation method (Chemiluminescent Nuclear Acid Detection Module, Pierce, Rockford, IL). Three to five independent experiments were done for each binding site.
The firefly luciferase reporter pGL3-Basic Vector and Renilla were purchased from Promega (Madison, WI). The empty and RUNXs expression vectors, pEF-BOS, pEF-BOS-HA-RUNX1, and pEF-BOS-RUNX2 were kind gifts from Dr. Ito [19, 20]. The entire promoter region of LGALS3 was amplified from human genomic DNA by PCR with the following primers: sense 5′-GCG CCTCGAGTCCAGGCCAGC-3′, antisense 5′-GCGCA AGCTTACCCTCTCCGGAC. pGL3-LGALS3 was constructed by inserting the intact 989 bp of the human LGALS3 promoter region in the pGL 3 basic vector between the XhoI and HindIII sites. Site-directed mutagenesis was performed with a kit from Stratagene (QuickChange II, La Jolla, CA) with the following primers: Primer 1 for Region 1 site 1: Sense 5′-AGGCCAGCA GATTTGATGTCTccTGAGGGCCTGC-3′, Antisense 5′-GCAGGCCCTCAggAGACATCAAATCTGCTGGCCT-3′; Primer 2 for Region 1 site 2: Sense 5′-GAGGGCCTGCTT TCTccTTCACAGAGGGAGCC-3′, Antisense 5′-GGCTCC CTCTGTGAAggAGAAAGCAGGCCCTC-3′; Primer 3 for region 5: Sense 5′-TGAGGCTCGGAGCCAggGCCCCG CC-3′, Antisense 5′-GGCGGGGCccTGGCTCCGAGCCTC A-3′. Mutated nucleotides were in lower case, from gg to cc or vice verca.
HeLa and SK-BR-3 cells were plated in 6-well plates at 200,000 cells/well with antibiotics-free media. Transient transfection was performed, respectively, with pGL3-LGALS3-Luc and pEF-BOS-HA-RUNX1, pEF-BOS-RUNX2, or pEF-BOS using the TransIt-LT1 reagent (Mi-rus, Madison, WI). Mock-transfected cells were used as control. Simian Virus 40-Renilla luciferase (phRL-SV40; Promega) plasmids were included in the HeLa and SK-BR-3 experiments as internal controls for transfection efficiency. Cells were lysed in passive lysis buffer 48 h post-transfection and tested with a Dual-Glo Luciferase Assay System according to the manufacturer’s protocol (Promega Corporation, Madison, WI) by using a TD-20e luminometer (Turner Designs Inc., MT. View, CA). Luciferase activity was normalized to Renilla activity to control for transfection efficiency variation. To identify the key nucleotides in the binding motifs, mutant types of pGL3-LGALS3 were also transfected and tested with the same procedures.
To determine whether downregulation of RUNX1 or RUNX2 could inhibit LGALS3 expression in pituitary tumor, siRNA of RUNX1 and RUNX2 were transfected into HP75 cells, and the expression of RUNX1, RUNX2, and Gal-3 mRNAs were tested by RT-PCR. Validated siRNA (on-Target plus) duplex oligoribonucleotide against RUNX1, RUNX2, negative control (Non-targeting), and positive control (GAPDH) were synthesized by Dharmacon (Lafayette, Colo). The sequences are as follows: (i) RUNX1 (Genbank NM_001754.3) sense 5′-UGACAACCCUCUCU GCAGAUU-3′, antisense 5′-UCUGCAGAGAGGGUUGU CAUU-3′; (ii) RUNX2 (Genbank NM_001015051) sense 5′-CAAGGACAGAGUCAGAUUAUU-3′, antisense 5′-U AAUCUGACUCUGUCCUUGUU-3′; (iii) GAPDH (NM-002046) 5′-GUCAACGGAUUUGGUCGUA-3′. The duplex oligoribonucleotide were re-suspended in siRNA buffer provided by Dharmacon to make a 20 μM solution and stored at −20°C till further use. siRNAs were used at a final concentration of 100 nM. HP 75 cells were transfected in a 12-well plate at approximately 50% confluent using the DharmaFECT1 transfection reagent (Dharmacon) according to the manufacturer’s protocol. Transfections were carried out for 48 h in serum and antibiotic-free media. Knock-down of RUNX1, RUNX2, and Gal-3 mRNA was confirmed by RT-PCR. All experiments were performed in triplicates and repeated 3 times.
All PCR products in ChIP assays, plasmid constructs, and site-directed mutagenesis products were sequenced for confirmation.
HP 75 cells plated in six-well plates were grown for 96 h after transfection with RUNX1, RUNX2 siRNA as described above. The cells were then incubated in fresh medium and [3H] thymidine for 5 h (5 uCi/ml). The cells were harvested, washed three times in PBS, and 1 ml of PBS was added to each pellet for cell counting. Ten thousand cells were placed in each scintillation vial, vortexed, and counted in a scintillation counter (Beckman Instruments Inc., Palo Alto, CA). All experiments and controls were performed in duplicate with three separate experiments.
A total of 191 pituitary tumor tissues from patients who had surgery between 1990 and 2007 at Mayo Clinic, Rochester, MN, were used. Institutional review board permission was obtained. These included 39 corticotroph (ACTH), 49 lactotroph (PRL), 47 gonadotroph (GTH), and 56 null cell (NC) tumors. Tissue microarrays were constructed as previously described . Briefly, 0.6 mm cores from selected blocks of formalin-fixed, paraffin-embedded tissue were taken in triplicate and placed in the TMA block. TMA sections cut at 4 μm were used for immunohistochemical staining. Antigen retrieval was performed by microwaving in 0.1 mM citrate buffer at pH 6.0 for 5 min. Antibodies used for TMA slides included Gal-3 (1:500, Vector Laboratories, Burlingame, CA), RUNX1, and RUNX2 (1:20 and 1:50, Calbiochem, La Jolla, CA). Immunostaining was performed with the avidin biotin peroxidase complex method (Vector Corp., Burlingame, CA), and diaminobenzidene was used as the chromogen. Evaluation of immunohistochemical results was performed by grading the intensity of staining on a scale of 0–4 with 0 for negative staining, 1+ for weak staining, 2+ for moderate staining, 3+ for strong staining, 4+ for very strong staining. The TMA triplicates were then averaged. Substitution of the primary antibody with normal serum was used as negative control for immunohistochemical staining. The specificity of each antibody was evaluated by Western blotting.
Because Gal-3 and RUNX1, 2, 3 were all highly expressed in some specific type of pituitary tumors, we designed a series of ChIP assays to determine if RUNX proteins could bind to the promoter region of LGALS3 in the HP75. Five pairs of primers were designed to amplify the LGALS3 promoter DNA. These 5 primers overlapped each other, covering all regions during the ChIP assays to determine if there was binding between RUNXs and LGALS3 promoter. We successfully amplified region 1 from the immunoprecipitated DNA with the anti-RUNX1 antibody as a 274 bp fragment (Fig. 1b). We also successfully amplified region 5 from the immunoprecipitated DNA with the anti-RUNX2 antibody as a 231 bp product (Fig. 1c). Although no binding motif was found in region 4, a 209 bp product (region 4) was also detected in pellets precipitated by anti-RUNX2 antibody (data not shown). All the 3 PCR products were confirmed by sequencing. There was no amplificatory product from the five regions from the immunoprecipitated DNA by anti-RUNX3 antibody. Beta-actin was not amplified in any ChIP assays except in the control input. These results confirmed that the fragments of LGALS3 promoter DNA were specifically pulled down by the anti-RUNX1 or anti-RUNX2 antibodies and not by carryover. The rabbit IgG immunoprecipitated pellets failed to amplify beta-actin or any fragment of LGALS3 promoter, further indicating that there was no non-specific binding.
EMSA supported the findings from ChIP assays. With one oligonucleotide derived from LGALS3 region 1, we found two shifted bands with the HP75 nuclear extract (Fig. 2a), probably from different isoforms (RUNX1 gene has at least 3 isoforms, AMLla 250AA, AML1b 453AA, AML1c 480AA) [22–25]; these two bands were ablated by a 200-fold excess of the cold oligonucleotide, indicating that they were specific binding sites. Adding anti-RUNX1 antibody slowed the migration of one band (super-shift), and confirmed the specific binding between this oligonucleotide and HP75 nuclear extract, but the other band disappeared. Similar to this finding, we also observed a shifted band on the oligonucleotide derived from LGALS3 region 5 (Fig. 2b), this band was ablated by 200-fold excess of its cold oligonucleotide, but we were not able to get a super-shifted band after adding anti-RUNX2 antibody.
Based on the ChIP and preliminary EMSA study results, we found that both RUNX1 and RUNX2 bind to the promoter region of LGALS3, but how the bindings affect expression of LGALS3 was uncertain. We then mutated the binding consensus sequence in EMSA probes, and repeated the experiments. We found that mutated region 1 probe in the first binding site lost its binding for LGALS3, while mutated region 1 probe in the second binding site significantly decreased the binding (Fig. 2c). Mutated region 5 probe also lost the ability to bind HP75 nuclear extract (Fig. 2d). These results indicated that these binding sites are sequence specific.
The full length LGALS3 promoter  was then cloned into pGL3 Basic vector, a luciferase reporter construct without promoter. This construct showed high luciferase activity, indicating that it was a real promoter. The reporter construct was then co-transfected with pEF-BOS or pEF-BOS-HA-RUNX1 or pEF-BOS-RUNX2 in Hela cells which express low level or lack endogenous RUNX1 activity [24, 26]. There was significantly increased luciferase activity in the cells transfected with RUNX1 and RUNX2 vector compared to the empty vector (Fig. 3a). In co-transfection with the RUNX1 vector, luciferase activity increased ~3.9 times, while in co-transfection with RUNX2 vector, the luciferase activity increased ~2.5 times. With increasing dosages of RUNX1 or RUNX2, luciferase activity was also increased (Fig. 3b). We repeated this co-transfection experiment in SK-BR-3, which does not express endogenous Gal-3, and obtained the same results, luciferase activity increased 4.8 and 6.2 times by RUNX1 and RUNX2 separately (Fig. 3a, b). We chose HeLa and SK-BR-3 rather than HP75 because HP75 expresses high levels of endogenous RUNX1, RUNX2, and Gal-3 which may have higher background to these analyses. These experiments demonstrated that both RUNX1 and RUNX2 can upregulate Gal-3. Since the CC (or GG) binucleotides are the most important ones in the binding consensus sequence [10, 15–18], we further mutated the consensus sequence in Region 1 (TCTGGT → TCTccT) and Region 5 (CACCGCC → CAggGCC). There was a significant decrease of luciferase activity in the co-transfection experiments (Fig. 3c, d), indicating that these short DNA sequences are responsible for the interactions between RUNXs and LGALS3 promoter. These data support the hypothesis that RUNXs specifically regulate LGALS3 expression driven by the regulatory region.
We used the HP75 as a pituitary tumor model, and knocked down RUNX1 and RUNX2 by siRNA. In the RNA interference experiments, there was a significant decrease in Gal-3 expression in HP75 cells after knock-down RUNX1 or RUNX2, indicating that both RUNX1 and RUNX2 upregulated LGALS3 in pituitary tumor cells (Fig. 4a, b).
To determine whether RUNX1 and RUNX2 play a role in pituitary tumor growth, [3H] thymidine incorporation experiments were performed in the HP75 cells. After siR-NA knock-down of RUNX1/RUNX2 for 96 h, HP75 cell proliferation was significantly decreased (Fig. 4c). This showed the importance of RUNX1 and RUNX2 in pituitary tumor growth.
Different subtypes of primary pituitary tumors were divided into two groups according to their Gal-3 expression level. There were 88 tumors in the Gal-3 high-expressing group which consisted of PRL and ACTH tumors, and 103 tumors in the Gal-3 low-expressing group which consisted of GH, FSH, LH, null cell, and TSH tumors. In the normal pituitary Gal-3 was produced only by PRL, ACTH, and folliculostellate cells. RUNX1 and RUNX2 immunostaining was scored in each group and compared between the two groups. There was a significant correlation between Gal-3 and RUNX1/RUNX2 expression levels (Fig. 4d).
A large body of evidence has shown roles of Gal-3 in tumor progression and metastasis [1, 27, 28]. Recently, Gal-3 expression has emerged as a potential diagnostic and/or prognostic marker for some cancers, such as thyroid cancers . Previously we reported that Gal-3 was expressed in a subset of normal pituitary cells, including lactotroph (PRL), corticotroph (ACTH), and folliculo-stellate (FS) cells. We also showed that Gal-3 had a role in the development of pituitary tumors [8, 9]. Treatment with transforming growth factor beta 1, which regulates pituitary cell proliferation, reduced Gal-3 as well as p27 expression levels in cultured HP75 pituitary tumor cells . Inhibition of LGALS3 gene expression by RNA interference also decreased HP75 cell proliferation and increased apoptosis . Consistent with this, a study from Roncaroli  demonstrated expression of Gal-3 in pituitary tumors derived from folliculostellate cells. These findings suggest that Gal-3 has an important regulatory role in pituitary tumor cell development and progression. The present studies show that RUNX1 and RUNX2 also have regulatory roles on Gal-3 expression in pituitary tumors.
The RUNX family members are important transcription factors which share a common partner, core-binding factor-β (CBF β). They are characterized by a highly conserved 128-amino-acid region homologous to the Drosophila protein Runt . The Runt domain is responsible for DNA binding, protein–protein interaction, ATP binding, and contributes to nuclear localization [32–34]. In mammals, the RUNX family comprises three genes, encoding for RUNX1, RUNX2, and RUNX3. These proteins play crucial roles in regulating distinct developmental pathways. RUNX1 is important for hematopoiesis [35, 36], RUNX2 is a fundamental transcription factor for osteogenesis [37, 38], and RUNX3 is crucial for gastrointestinal organogenesis and neurogenesis [39, 40]. RUNX also has a role in tumor proliferation and progression, but whether they are oncogenes or tumor suppressor genes remains controversial. It is possible that their role as oncogenes and/or tumor suppressor genes is context-dependent. Studies in mouse skeletal system by Stock et al  indicated that RUNX2 protein regulates LGALS3 through binding to its promoter region. We questioned whether RUNX2 and possibly its family members, RUNX1 and RUNX3, could regulate LGALS3 and play a role in human pituitary tumor development.
ChIP assays showed that there was binding between RUNX1, RUNX2 proteins and LGALS3 promoter in the human pituitary tumor cell line HP75. RUNX1 binds to an upstream region on LGALS3 promoter which contains the predicted RUNX1 binding consensus sequence “TCTG GT”; RUNX2 binds to a downstream region which contains the predicated RUNX2 binding consensus sequence “CACCGCC.” We also observed that the anti-RUNX2 antibody pulled down the region 4 in the LGALS3 promoter in which there is no binding sequence predicted by the softwares; however, the binding sequence in region 5 is very close to region 4, with only 5 base pair distances. Considering the DNA length after sonication is generally 200–500 bp, and our PCR products are 200–300 bp, it is reasonable to observe this precipitation of region 4 by anti-RUNX2 antibody. These results were supported by EMSA experiments, which showed that the synthetic oligonucleotides containing “TCTGGT” or “CACCGCC” specifically bind to HP 75 nuclear extract. We also identified the key nucleotides in the binding sequences, since mutations from “TCTGGT” to “TCTccT” or “CACCG CC” to “CAggGCC” completely abolished these bindings. Anti-RUNX1 antibody slowed one band in region 1 probe further strengthening the hypothesis of specific binding between RUNX1 and region 1; but anti-RUNX1 failed to slow the other band. In contrast, the antibody eliminated this protein/DNA binding. The reason could be that, anti-RUNX1 antibody binds to the same site of this isoform of RUNX1 protein which also binds the oligonucleotides, so adding antibody interrupted the formation of a DNA/RUNX1 complex. In EMSA with region 5 probe, anti-RUNX2 also failed slowing the band but ablated the protein/DNA binding. The reason is probably the same as in RUNX1 experiment. These experiments provided evidences for a role of RUNX1 and RUNX2 in pituitary tumor development.
Proliferation studies using [3H] thymidine incorporation provided more biological evidence of the regulatory role of RUNX1 and RUNX2 in pituitary tumor, because knockdown of RUNX1 and RUNX2 in HP75 cells significantly decreased the cell growth.
There is increasing evidence that RUNXs are involved in the development of tumors, where they act as either oncogenes or tumor suppressor genes depending on the context. Amplification of RUNX1 has been linked with poor prognosis in childhood B-cell leukemia , while RUNX2 expression has been implicated in bone metastasis of breast cancer . One study has also shown that the ability to induce premature senescence in primary murine embryonic fibroblast is a common feature of all three RUNX genes . A more recent study demonstrated that both RUNX1 and RUNX2 but not RUNX3 are highly expressed in human glioma cells; this study also showed that RUNX2 mediates expression of Galectin-3 in glioma . Therefore, elucidating the signaling pathway of the RUNX genes is very important. Here, we showed that LGALS3, which is an oncogene and plays critical roles in many cancers, is a direct target gene of RUNX1 and RUNX2.
In summary, we showed for the first time that LGALS3 is upregulated by RUNX1 and RUNX2 in human pituitary tumors and that different RUNX family member binds different DNA sequences in the LGALS3 promoter region. These studies suggest that RUNX1 and RUNX2 upregulate LGALS3 by direct binding to its promoter region and contribute, in part, to pituitary tumor growth regulation.
This research was supported in part by NIH Grant CA90249 and a Grant from the Jarislowsky Foundation to RVL) and NIH Grant R37CA46120-19 (to AR).
He-Yu Zhang, Department of Pathology, Mayo Clinic College of Medicine, 200, 1 Street SW, Rochester, MN 55905, USA.
Long Jin, Department of Pathology, Mayo Clinic College of Medicine, 200, 1 Street SW, Rochester, MN 55905, USA.
Gail A. Stilling, Department of Pathology, Mayo Clinic College of Medicine, 200, 1 Street SW, Rochester, MN 55905, USA.
Katharina H. Ruebel, Department of Pathology, Mayo Clinic College of Medicine, 200, 1 Street SW, Rochester, MN 55905, USA.
Kendra Coonse, Department of Pathology, Mayo Clinic College of Medicine, 200, 1 Street SW, Rochester, MN 55905, USA.
Yoshinori Tanizaki, Department of Pathology, Mayo Clinic College of Medicine, 200, 1 Street SW, Rochester, MN 55905, USA.
Avraham Raz, Tumor Progression and Metastasis Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
Ricardo V. Lloyd, Department of Pathology, Mayo Clinic College of Medicine, 200, 1 Street SW, Rochester, MN 55905, USA.